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Abstract
Advanced glycation end products (AGEs) may contribute to the development of type 2 diabetes
and related complications, whereas their role in the early deterioration of glycaemia is unknown.
While previous studies used antibody-based methods to quantify AGEs, data from tandem
mass spectrometry coupled liquid chromatography (LC-MS/MS)-based measurements are
limited to patients with known diabetes. Here, we used the LC-MS/MSmethod to test the hy-
pothesis that plasma AGE levels are higher in individuals with impaired fasting glucose (IFG)
than in those with normal fasting glucose (NFG). Secondary aims were to assess correlations
of plasma AGEs with quantitative markers of glucose metabolism and biomarkers of subclinical
inflammation. This study included on 60 women with NFG or IFG (n = 30 each, mean age
74 years) from the German SALIA cohort. Plasma levels of free metabolites (3-deoxyfructose,
3-deoxypentosone, 3-deoxypentulose), two hydroimidazolones, oxidised adducts (carboxy-
methyllysine, carboxyethyllysine, methionine sulfoxide) and Nε-fructosyllysine were measured
using LC-MS/MS. Plasma concentrations of all tested AGEs did not differ between the NFG
and IFG groups (all p>0.05). Associations between plasma levels of AGEs and fasting glucose,
insulin and HOMA-IR as ameasure of insulin resistance were weak (r between -0.2 and 0.2, all
p>0.05). The association between 3-deoxyglucosone-derived hydroimidazolone with several
proinflammatory biomarkers disappeared upon adjustment for multiple testing. In conclusion,
plasma AGEs assessed by LC-MS/MSwere neither increased in IFG nor associated with pa-
rameters of glucosemetabolism and subclinical inflammation in our study. Thus, these data
argue against strong effects of AGEs in the early stages of deterioration of glucosemetabolism.
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Introduction
The causes and risk conditions of type 2 diabetes (T2D) are manifold, but on the molecular
level they all lead to impaired insulin signalling and/or insulin secretion ultimately resulting in
hyperglycaemia. With the loss of glycaemic control, the risk of diabetes comorbidities like
macro- and microvascular complications increases. Accumulating evidence supports the rele-
vance of advanced glycation end products (AGEs) in the development and progression of
these complications.
Hyperglycaemia, but also hyperlipidaemia and oxidative stress, accelerate formation of
AGEs by nonenzymatic glycation reactions [1–3]. Excessive AGE accumulation can deteriorate
tissue function by interfering with activities of glycated macromolecules and enzymes and by
binding to surface receptors for AGEs (RAGE) on leukocytes triggering oxidative stress and in-
flammatory responses [4]. Subclinical inflammation in turn represents an important risk factor
in the development of T2D and related complications [5–7].
Apart from endogenous AGE formation, smoking tobacco products [8, 9] and consumption
of heat-processed food and beverages [10] also increases levels of AGEs and their precursor
molecules. It was estimated that the daily intake of AGEs ranges between 25 and 75 mg per
day, which are partly absorbed from the gastrointestinal tract [11, 12]. Smoking is related to ox-
idative stress, upregulation of receptors for advanced glycation end products (RAGE), inflam-
mation and increased AGE formation in extrapulmonary tissue [13].
Methylglyoxal-derived hydroimidazolone (MGH) and Nε-carboxymethyllysine (CML) are
likely the most abundant AGEs. Levels of MGH range from 43 to 421 nmol/l in the circulation
in healthy and diabetes patients [14], and levels of CML range from 27 to 114 nmol/l. It has to
be noted that an absolute quantification of AGEs is challenging, because they depend on both
assay type and sample preparation. Due to the complex sample preparation for liquid chroma-
tography assays, epidemiological studies tend to use antibody-based assays to characterise gly-
cated and oxidised protein amounts, which are easy to handle and less expensive. However,
these assays often lack specificity.
To date it is not clear to what extent AGEs merely reflect hyperglycaemia or contribute
actively to the progression of diabetes. In addition, it is not known whether AGEs contribute
only to diabetic complications or are also involved in the early deterioration of glucose homeo-
stasis. Preliminary evidence suggests that AGEs from endogenous glycation reactions or exter-
nal sources may be involved in beta-cell injury [15] and peripheral insulin resistance [16] and
may thereby contribute to the development impaired fasting glucose and impaired glucose tol-
erance. Of note, that these states of higher diabetes risk are already associated with increased
prevalence of micro- and macrovascular diabetes-related complications [17].
To explore the role of AGEs in the context of glucose metabolism and systemic inflamma-
tion, this cross-sectional study was established to measure AGE levels by highly sensitive and
precise liquid chromatography coupled mass spectrometry (LC-MS)-based methods. This
study was designed as pilot study with the primary aim to test the hypothesis that plasma levels
of AGEs are already increased in individuals with mild hyperglycaemia (i.e. IFG compared to
NFG). As secondary aims, we wanted (i) to assess associations between plasma AGEs and
quantitative measures of glucose metabolism (i.e. fasting glucose, fasting insulin levels and
HOMA-insulin resistance) and (ii) to investigate correlations between plasma AGEs and plas-
ma levels of biomarkers of subclinical inflammation.
AGEs and Impaired Fasting Glucose
PLOS ONE | DOI:10.1371/journal.pone.0128293 May 27, 2015 2 / 15
SALIA received funds from the Ministry of the
Environment of the State of North Rhine-Westphalia
(Düsseldorf, Germany) and the Federal Ministry of
the Environment (Berlin, Germany). The follow-up
investigation was funded by the DGUV (German
statutory accident assurance) VT 266.1. This work
was supported by the Ministry of Science and
Research of the State of North Rhine-Westphalia
(MIWF NRW), the German Federal Ministry of Health
(BMG) and in part by a grant from the German
Federal Ministry of Education and Research (BMBF)
to the German Center for Diabetes Research (DZD e.
V.). The funders had no role in study design, data
collection and analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: The authors of this manuscript
have the following competing interests: Christian
Herder is Editorial Board member of PLOS ONE.
Study Population and Methods
Study design and population
We performed a cross-sectional pilot study within a subgroup of 60 non-diabetic and non-
smoking women participating in the follow-up examination of the SALIA study in 2008/09
[18]. From 363 women with available plasma samples from this examination, we excluded pa-
tients with diabetes because the study focused on mild hyperglycaemia. Current smokers were
excluded in order to prevent confounding effects from smoking as major determinant of AGE
levels. From the remaining non-smoking women with normal fasting glucose (NFG, n = 178)
or impaired fasting glucose (IFG, n = 132) we randomly selected 30 from each group for this
study. IFG was defined according to the guidelines of the American Diabetes Association [19].
Written informed consent from all study participants was collected. The study was approved
by the ethics board of the Ruhr University in Bochum (Germany).
As described before, anthropometric measurements (height, weight) were conducted ac-
cording to standardised protocols [20]. Additional data were collected using an extensive inter-
view and questionnaire. Information about the women’s socioeconomic status was assessed by
the maximum period of education achieved by the participants or their spouses (<10 years vs.
10 years). Classification of smoking habits was performed according to the possible answers
“never smokers”, “passive smokers (home, workplace)”, “past smokers” or “current smokers”,
with active smokers excluded for this pilot study as described above.
Measurement of parameters of glucose metabolism
Plasma was stored at -80°C directly after blood collection and used for all assays which have
been described in detail before [18]. Fasting plasma glucose levels were determined on a
Roche/Hitachi Cobas c 311 analyzer (Basel, Switzerland). Plasma insulin was measured by
ELISA (Mercodia, Uppsala, Sweden). As surrogate marker of insulin resistance, the homeosta-
sis model assessment-insulin resistance (HOMA-IR) was calculated as fasting glucose (mmol/
L)  fasting insulin (μU/ml) / 22.5.
Measurement of immune mediators
Plasma levels of high sensitive CRP (hsCRP) were determined on a Roche/Hitachi Cobas c 311
analyzer. Interleukin 6 (IL-6), IL-8, tumour necrosis factor (TNF) α, leptin, IL-1 receptor an-
tagonist (IL-1ra), transforming growth factor β1 (TGF-β1), total adiponectin, high-molecular-
weight (HMW) adiponectin, soluble E-selectin (sE-selectin) and soluble intracellular adhesion
molecule 1 (sICAM-1) were measured using Quantikine (IL-1ra, TGF-β1, total adiponectin,
HMW adiponectin, leptin, sE-selectin, sICAM-1) or Quantikine HS (IL-6, IL-8, TNFα) ELISA
kits (R&D Systems, Wiesbaden, Germany) as described [18]. Plasma IL-18 was quantified with
the ELISA kit fromMBL (Nagoya, Japan). Plasma concentrations of macrophage chemoattrac-
tant protein-1 (MCP-1) and interferon gamma-induced protein 10 (IP-10) were assessed by
bead-based multiplex assays [18] using a Bio-Plex 200 System controlled by Bio-Rad Bio-Plex
Manager Software 6.0 from Bio-Rad Laboratories (Hercules, CA). Bead-based assays (Human
Obesity Base Kit and Human Cytokine Custom Premix Kit A) were acquired from R&D
Systems.
Measurement of AGEs
Non-protein-bound glucose metabolites by GC-MS. Molecular levels of 3-deoxyfructose
(3-DF), 3-deoxypentosone (3-DPs) and 3-deoxypentulose (3-DP) in plasma were measured by
gas chromatography coupled with mass spectrometry (GC-MS) as described [21]. First, soluble
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proteins in plasma were removed by precipitation after adding 10 μL internal standard (IS) of
methyl-α-D-galactopyranoside (MGP) and 180 μL acetonitrile/methanol (7:3, v/v) mixture to
100 μL plasma. The solution was stored for 30 minutes on ice and centrifuged for 10 minutes at
4500 g and 4°C. 150 μL of clear supernatant were evaporated overnight to dryness under nitro-
gen flow at 40°C. The dried mixture was resolved and vortexed with 50 μL hydroxyl amine
(10 mg/mL pyridine) agent and again evaporated to dryness under the same conditions as be-
fore. The dried compounds were prepared for gas chromatography by adding 50 μL N,O-bis
(trimethylsilyl)trifluoroacetamide (BSTFA) and incubating this mixture for 2 hours at room
temperature. The samples were diluted to a final volume of 100 μL by adding 50 μL n-hexane.
The silylated solution was measured within the next 12 hours.
GC-MS analysis was performed on an Agilent 6890 series gas chromatograph, coupled with
a 7683 series injection system as well as a 7683 series autosampler. An Agilent 5973 series mass
detector with electron impact ionisation (Palo Alto, CA) was used for mass detection. Details
regarding the configuration were described before [21]. The temperature gradient was modi-
fied in line with our analytes and temperature increased by 7 K/min.
Amino adducts. Plasma proteins were hydrolysed prior mass detection by tandem mass
spectrometry coupled liquid chromatography (LC-MS/MS). Enzymatic hydrolysis was per-
formed within 96 hours as described [22]. For this purpose 10 μL IS (13C6-3-DGH,
13C6-
MGH1, D2-CML,
13C6,15N2-FruLys), 500 μL 0.02 N HCl and 25 μL pepsine solution were
added to 20 μL plasma sample. Oxygen-free atmosphere was realised by perfusing the mixture
for 15 seconds and the tube for 10 minutes with nitrogen. After incubating the solution for
24 hours at 37°C, 125 μL potassium-phosphate buffer, 25 μL 0.26 M KOH and 25 μL pronase
E solution were added for the second step. The oxygen was removed again from the solution.
The mixture was returned to the incubation chamber where it remained for another 24 hours
at 37°C. An aliquot of 5 μL prolidase and 4 μL aminopeptidase were added for the last step of
hydrolysis. Again oxygen was removed from the reaction tube and was restored at the incuba-
tion chamber at 37°C for 48 hours. The hydrolysate was stored at -80°C prior analysis.
The determination of the hydroimidazolones methylglyoxal-derived hydroimidazolone-1
(MGH1), 3-deoxyglucosone-derived hydroimidazolone (3-DGH), oxidised adducts carboxy-
methyllysine (CML), carboxyethyllysine (CEL), methionine sulfoxide (MetSO) and the precur-
sor molecule Nε-fructosyllysine (FruLys) was performed with the hydrolysed plasma sample.
For these measurements an aliquot of 100 μL was taken from the defrosted solution and filtered
by a regenerated cellulose (RC) 0.2 μm syringe filter into an HPLC vial with a 200 μL insert.
Due to the unstable properties of glycation adducts against atmospheric oxygen, the prepared
sample was measured within 12 hours after defrosting.
Parameters for the chromatographic assay and mass spectrometry were adapted from previ-
ous studies [23]. We performed measurements on an Agilent 1200 series LC module with an
Agilent 6410 series mass detector.
Amino acids. To calculate the glycation rate of plasma proteins it was necessary to deter-
mine the amino acid levels after enzymatic hydrolysis in the samples. Therefore a 50 μL aliquot
was taken from the solution after precipitation and 100 μL of lithium citrate buffer were added.
The mixture was stored at 8°C for 12 hours and then centrifuged at 4500 g for 10 minutes to
separate the solution from sediments. The clear supernatant was used for analysis on a Sykam
S4300 (Sykam, Eresing, Germany) amino acid reaction module for amino acid analysis.
Statistical analyses
Descriptive statistics were conducted after stratification into participants with NFG and IFG.
All continuous variables of inflammation, protein glycation as well as oxidation did not follow
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a Gaussian distribution and are therefore given as median values and 25th/75th percentiles. For
further analyses (t-tests, regression and correlation analyses), these variables were log-trans-
formed to the base of 2. Hydroimizalones were determined as molar amount of affected amino
acid [nmol/mol]. Further products of protein glycation or oxidation were presented as total
amount in plasma [μmol/L].
We applied the parametric Student’s t-test to assess unadjusted differences between both
groups (NFG and IFG). Linear regression models were used to assess differences of plasma lev-
els of AGEs or inflammation-related biomarkers between the NFG and IFG groups after ad-
justment for age, BMI, education, smoking status and passive smoking. Pearson correlation
coefficients based on log-transformed variables if appropriate (see above) were computed for
associations between AGEs and all other variables (AGEs, immunological mediators and mark-
ers for glucose metabolism [fasting glucose, fasting insulin and HOMA-IR]) in plasma. We cal-
culated partial correlations coefficients in addition to adjust for confounding variables.
Post-hoc power was calculated by using GPower 3.1 in order to evaluate the achieved
power of the generated results in this pilot study. Calculations were performed according to the
software protocol assuming a two-sided level of significance of α = 0.05 and the achieved effect
size between NFG and IFG group for each biomarker.
All provided p values are two-sided. P values<0.05 were considered to indicate statistical
significance. All statistical analyses were performed using SAS statistics 9.3 (SAS Institute,
Cary, NC).
Results
Description of the study population
Characteristics of the study population stratified by fasting glucose levels are summarised in
Table 1. Both groups did not differ by age, but women with IFG had a higher body mass index
(BMI) than women with NFG (p = 0.0008). As expected, fasting glucose, fasting insulin and
HOMA-IR were higher in the IFG group (all p<0.0001). Both groups did not differ with re-
spect to level of education, smoking status and exposure to passive smoking.
Biomarkers of subclinical inflammation in individuals with NFG and IFG
Plasma concentrations of pro- and anti-inflammatory immune mediators are presented in
Table 2. The IFG group showed higher plasma levels of leptin (p<0.0001) and TNFα
(p = 0.0292) than the NFG group and a lower ratio of HMW/total adiponectin (p = 0.0085),
whereas no significant differences were observed for the other biomarkers. Adjusting for age,
BMI, smoking status, passive smoking and education had no effect on these results.
AGE levels in individuals with NFG and IFG
Plasma concentrations of free metabolites (3-DF, 3-DPs, 3-DP), hydroimidazolones (MGH1,
3-DGH), oxidised adducts (CML, CEL, MetSO) and the precursor molecule FruLys did not dif-
fer between the NFG and IFG groups (all p>0.05, Table 3). Adjustment for age, BMI, smoking
status, passive smoking and education did not change these results.
Table 4 demonstrates that most AGEs were not correlated with each other. We found posi-
tive correlations for CML and CEL (r = 0.74), 3-DPs and 3-DF (r = 0.48), MGH1 and CML
(r = 0.38) as well as MetSO and FruLys (r = 0.29), whereas a negative correlation was observed
for FruLys and MGH1 (r = -0.32).
AGEs and Impaired Fasting Glucose
PLOS ONE | DOI:10.1371/journal.pone.0128293 May 27, 2015 5 / 15
Association of plasma AGEs with parameters of glucose metabolism
and subclinical inflammation
Associations between plasma levels of AGEs and fasting glucose, fasting insulin and HOMA-IR
were weak (r between -0.2 and 0.2) and not statistically significant (all p>0.05) (Table 5). We
Table 1. Characteristics of the Study Population Stratified by Fasting Glucose Levels.
Variable Women with normal fasting glucose Women with impaired fasting glucose p
N 30 30
Age [years] 73.9 ± 2.3 74.7 ± 2.7 0.1916
BMI [kg/m2] 26.0 ± 4.0 30.3 ± 4.2 0.0001
Fasting glucose [mg/dl] 90.3 (86.5; 92.5) 110.0 (103.5; 115.5) <0.0001
Fasting insulin [μU/ml] 5.4 (4.5; 6.7) 7.7 (6.6; 10.3) <0.0001
HOMA-IR 1.2 (0.9; 1.5) 2.1 (1.9; 2.9) <0.0001
<10 years education [%] 26.7 34.5 0.7911
Smoking (current/former/never) [%] 0.0/3.3/96.7 0.0/16.7/83.3 0.1945
Passive smoking [%] 26.7 43.3 0.2789
The table shows characteristics of the study population: n = 30 with normal fasting glucose, n = 30 with impaired fasting glucose. Data represent mean
values ± standard deviation, median with 25th and 75th percentiles, or percentages. The p value indicates statistical differences between both groups for
the respective variables.
doi:10.1371/journal.pone.0128293.t001
Table 2. Plasma Concentrations of ImmuneMediators Stratified by Fasting Glucose Levels.
Immune mediator Women with normal fasting glucose Women with impaired fasting glucose p* p**
Acute-phase protein
hsCRP [mg/dL] 0.2 (0.1; 0.4) 0.2 (0.2; 0.4) 0.7252 0.6766
Proinflammatory cytokines
IL-6 [pg/mL] 1.0 (0.8; 2.4) 1.6 (1.0; 2.4) 0.5365 0.5589
IL-18 [pg/mL] 208 (169; 301) 241 (185; 326) 0.2114 0.2172
TNFα [pg/mL] 1.2 (0.9; 1.9) 1.4 (1.1; 2.0) 0.0292 0.0234
Leptin [ng/mL] 12.3 (8.1; 16.3) 21.4 (15.6; 31.7) <0.0001 <0.0001
Antinflammatory cytokines
IL-1ra [pg/mL] 218 (165; 274) 256 (182; 322) 0.1770 0.1050
TGF-β1 [ng/mL] 4.8 (3.2; 7.9) 5.6 (3.3; 8.1) 0.9161 0.9365
Total adiponectin [μg/mL] 8.0 (5.9; 11.4) 9.2 (7.4; 12.5) 0.7163 0.8972
HMW adiponectin [μg/mL] 4.9 (3.2; 7.4) 3.9 (2.9; 5.4) 0.1429 0.1092
Ratio HMW/total adiponectin 0.54 (0.48; 0.64) 0.43 (0.34; 0.60) 0.0085 0.0133
Chemokines
MCP-1/CCL2 [pg/mL] 119 (92; 155) 128 (115; 161) 0.3002 0.2633
IP-10/CXCL10 [pg/mL] 50.2 (38.6; 61.9) 44.6 (35.3; 59.7) 0.8604 0.7448
IL-8/CXCL8 [pg/mL] 10.1 (7.6; 12.6) 11.1 (8.4; 13.1) 0.7134 0.8488
Soluble adhesion molecules
sE-selectin [ng/mL] 22.6 (20.3; 32.1) 28.2 (23.1; 35.9) 0.5168 0.5684
sICAM-1 [ng/mL] 206 (181; 245) 190 (164; 216) 0.0778 0.0766
Data are given as median with 25th and 75th percentiles;
* unadjusted p value;
** p value adjusted for age, BMI, smoking status, passive smoking and education.
doi:10.1371/journal.pone.0128293.t002
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found some evidence that particularly 3-DGHmay be positively correlated with several proin-
flammatory biomarkers, but adjustment for multiple tests (12x18 correlations in Table 5) ren-
dered these associations not significant anymore.
Discussion
This pilot study analysed the associations between AGEs and mild hyperglycaemia in study
participants with NFG and IFG. Plasma AGE levels of FruLys, 3-DF, 3-DPs, 3-DP, MGH1,
3-DGH, CML, CEL and MetSO were independent of fasting glycaemia as well as fasting insulin
and HOMA-IR as a surrogate of insulin resistance. Furthermore, correlations between plasma
AGE concentrations and biomarkers of subclinical inflammation were rather weak in unad-
justed analyses and after adjusting for age, BMI, passive smoking, history smoking and
social status.
LC-MS/MS based measurements of AGEs in plasma
Protein-bound AGEs were detected by LC-MS/MS based measurements, which are character-
ised by their high specificity and sensitivity [24, 25]. Antibody-based AGE detection was estab-
lished in proteomic studies because of their easy and less time consuming sample preparation.
Reproducible results were obtained not only for CML, but also for levels of pyrraline [26] and
methylgloyxal-modified proteins [27–30] by highly specified immunochemical methods. A
brief overview of commonly used antibodies for AGE determination is provided by Nagai and
Horiuchi [31]. However, the accuracy of these immunoassays depends on the matrix [24, 25,
32] and the specificity of the antibodies. Several studies revealed that most of the antibodies
used for AGE measurements show some degree of cross-reactivity with other epitopes [25, 33]
and may thus yield misleading results.
Table 3. Plasma Concentrations of compounds of protein glycation and oxidation.
Analyte Women with normal fasting glucose Women with impaired fasting glucose p* p**
Precursor molecule
FruLys [mM] 3.5 (3.2; 3.8) 3.7 (3.2; 4.0) 0.3866 0.2982
Free metabolites
3-DF [μM] 2.7 (2.4; 3.7) 2.4 (1.9; 2.9) 0.1836 0.3058
3-DPs [nM] 18.8 (16.0; 21.1) 17.6 (13.5; 20.3) 0.0846 0.1283
3-DP [nM] 705.1 (389.9; 832.3) 720.3 (424.3; 912.9) 0.4756 0.5446
Hydroimidazolones
MGH1 [nmol/mmol Arg] 178.0 (104.2; 222.6) 200.8 (162.1; 259.3) 0.0763 0.0765
3-DGH [nmol/mmol Arg] 74.8 (28.5; 108.9) 62.5 (28.5; 104.8) 0.9544 0.9012
Oxidated adducts
CML [nM] 676.6 (554.1; 804.5) 688.0 (599.1; 809.7) 0.4400 0.4505
CEL [nM] 152.8 (137.1; 173.4) 169.0 (135.9; 131.3) 0.1409 0.1669
MetSO [mM] 2.1 (1.7; 3.2) 2.5 (1.7; 2.9) 0.8267 0.9188
Data are given as median with 25th and 75th percentiles;
* unadjusted p value;
** p value adjusted for age, BMI, smoking status, passive smoking and education.
3-DF, 3-deoxyfructose; 3-DPs, 3-deoxypentosone; 3-DP, 3-deoxypentulose; MGH1, methylglyoxal-derived hydroimidazolone 1; 3-DGH,
3-deoxyglucosone-derived hydroimidazolone; CML, carboxymethyl lysine; CEL, carboxyethyl lysine; MetSO, methionine sulfoxide; FruLys, Nε-
fructosyllysine.
doi:10.1371/journal.pone.0128293.t003
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Compared to previous works we observed overall lower AGE levels [23] as well as lower
concentrations for α-dicarbonyl compounds, but higher levels for 3-DF in plasma compared to
previous studies [34, 35]. This discrepancy may have resulted from differences between the
evaluated populations and from differences in preanalytical aspects of sample treatment [36].
With respect to free glucose metabolites, we demonstrate the presence of 3-DP in human
plasma. This result indicates that ribose or ribose-5-phosphate (R5P) may undergo in vivo
Maillard reaction as well [37] or that in vivo glucosone decomposition results in 3-DPs [38].
The susceptibility of R5P to undergo Maillard reaction might be several times increased com-
pared to glucose-6-phosphate (G6P), as the percentage of open chain carbohydrates is many
times higher at R5P than at G6P [39, 40]. Despite the reactivity of R5P, the concentrations of
3-DPs may be lower than levels of 3-DG, because the physiological R5P concentration reaches
only up to 10% of the physiological G6P concentration.
Associations between AGEs and parameters of glucose metabolism
We observed no statistically significant differences in plasma AGEs levels between the NFG
and IFG groups. However, we observed a trend towards higher MGH1 levels in IFG.
Table 4. Correlation Between Plasma Levels of AGEs.
3-DPs 3-DP MG H 3-DG H CML CEL MetSO FruLys
3-DF r 0.4791 -0.2235 -0.2551 -0.0773 -0.1212 -0.1123 -0.0766 -0.0766
p 0.0001** 0.0917* 0.0533* 0.5642 0.3647 0.4013 0.5676 0.5676
n 58 58 49 37 58 57 58 58
3-DPs r -0.0879 -0.1911 -0.1295 0.0697 0.1286 0.1296 0.0026
p 0.5115 0.1508 0.3328 0.6033 0.3362 0.3323 0.9846
n 58 49 37 58 57 58 58
3-DP r 0.1027 0.2168 0.1444 0.2084 0.0865 0.0945
p 0.4430 0.1021 0.2795 0.1164 0.5183 0.4805
n 49 37 58 57 58 58
MG H r 0.0035 0.3754 0.0765 -0.1113 -0.3191
p 0.9786 0.0031** 0.5615 0.3970 0.0130**
n 34 51 50 51 51
3-DG H r 0.1871 0.0981 -0.0899 -0.2521
p 0.1523 0.4561 0.4946 0.0520*
n 38 38 38 38
CML r 0.7397 -0.1021 0.0160
p <.0001** 0.4374 0.9034
n 59 60 60
CEL r 0.1856 0.1672
p 0.1557 0.2017
n 59 59
MetSO r 0.2907
p 0.0243**
n 60
Correlation coefficients r are presented with their corresponding p value. n, number of observations;
** p value <0.05;
* p-value between 0.05 and 0.1.
doi:10.1371/journal.pone.0128293.t004
AGEs and Impaired Fasting Glucose
PLOS ONE | DOI:10.1371/journal.pone.0128293 May 27, 2015 8 / 15
T
ab
le
5.
C
o
rr
el
at
io
n
B
et
w
ee
n
A
G
E
s,
G
lu
co
se
,I
n
su
lin
an
d
B
io
m
ar
ke
rs
o
fS
u
b
cl
in
ic
al
In
fla
m
m
at
io
n
.
F
as
ti
n
g
g
lu
co
se
F
as
ti
n
g
in
su
lin
H
O
M
A
-I
R
h
sC
R
P
IL
-6
IL
-1
8
T
N
F
α
L
ep
ti
n
IL
-1
ra
T
G
F
-β
1
T
o
ta
l
ad
ip
o
n
ec
ti
n
H
M
W
ad
ip
o
n
ec
ti
n
H
M
W
/t
o
ta
l
ad
ip
o
n
ec
ti
n
M
C
P
-
1
IP
-1
0
IL
-8
sE
-S
el
ec
ti
n
sI
C
A
M
-
1
F
as
ti
n
g
r
-
0.
60
3
0.
76
1
-0
.0
47
-0
.0
12
0.
22
3
-0
.0
16
0.
18
7
-0
.0
04
0.
11
7
-0
.2
56
-0
.3
15
-0
.1
57
0.
21
6
-0
.0
50
0.
21
8
0.
06
0
-0
.2
36
g
lu
co
se
p
-
<
.0
00
1
<
.0
00
1
0.
73
8
0.
93
3
0.
10
5
0.
90
9
0.
17
7
0.
97
9
0.
40
2
0.
06
2
0.
02
0
0.
25
8
0.
13
1
0.
72
9
0.
11
4
0.
66
4
0.
08
5
n
-
60
60
60
60
60
60
60
60
60
60
60
60
60
60
60
60
60
F
as
ti
n
g
r
0.
60
3
-
0.
97
7
-0
.0
14
-0
.0
79
0.
36
0
-0
.1
87
0.
24
8
0.
16
9
0.
25
7
-0
.3
90
-0
.4
52
-0
.1
97
0.
24
6
-0
.0
42
0.
17
6
0.
14
9
-0
.1
24
in
su
lin
p
<
.0
00
1
-
<
.0
00
1
0.
92
2
0.
57
5
0.
00
8
0.
17
7
0.
07
0
0.
22
1
0.
06
1
0.
00
4
0.
00
1
0.
15
2
0.
08
4
0.
77
4
0.
20
3
0.
28
2
0.
37
0
n
60
-
60
60
60
60
60
60
60
60
60
60
60
60
60
60
60
60
H
O
M
A
-I
R
r
0.
76
1
0.
97
7
-
-0
.0
24
-0
.0
67
0.
35
3
-0
.1
56
0.
25
2
0.
13
7
0.
24
0
-0
.3
87
-0
.4
53
-0
.2
03
0.
25
7
-0
.0
47
0.
20
2
0.
13
8
-0
.1
65
p
<
.0
00
1
<
.0
00
1
-
0.
86
5
0.
63
2
0.
00
9
0.
26
0
0.
06
6
0.
32
4
0.
08
0
0.
00
4
0.
00
1
0.
14
1
0.
07
2
0.
74
6
0.
14
3
0.
32
1
0.
23
3
n
60
60
-
60
60
60
60
60
60
60
60
60
60
60
60
60
60
60
3-
D
F
r
0.
06
6
-0
.0
32
-0
.0
09
0.
18
9
0.
03
1
-0
.0
51
-0
.0
48
0.
08
5
-0
.0
47
-0
.3
91
-0
.0
38
0.
06
5
0.
14
2
-0
.0
40
-0
.0
22
-0
.2
04
-0
.1
35
-0
.0
99
p
0.
64
3
0.
82
0
0.
95
0
0.
18
1
0.
82
8
0.
71
9
0.
73
4
0.
55
0
0.
74
0
0.
00
4
0.
78
7
0.
64
8
0.
31
7
0.
78
7
0.
88
5
0.
14
6
0.
34
1
0.
48
4
n
58
58
58
58
57
58
58
58
58
58
58
58
58
54
54
58
58
58
3-
D
P
s
r
-0
.0
15
0.
15
7
0.
12
4
-0
.0
52
-0
.1
21
-0
.2
31
-0
.1
75
0.
19
3
0.
21
2
-0
.1
40
-0
.1
65
-0
.1
57
-0
.0
34
-0
.0
39
-0
.0
45
-0
.1
06
-0
.0
24
-0
.0
07
p
0.
91
4
0.
26
6
0.
38
1
0.
71
5
0.
39
9
0.
10
0
0.
21
4
0.
17
1
0.
13
2
0.
32
4
0.
24
3
0.
26
6
0.
81
3
0.
79
1
0.
76
3
0.
45
5
0.
86
9
0.
96
0
n
58
58
58
58
57
58
58
58
58
58
58
58
58
54
54
58
58
58
3-
D
P
r
0.
00
0
0.
08
0
0.
06
5
-0
.0
51
-0
.0
60
-0
.0
88
0.
10
5
-0
.0
89
0.
09
1
0.
04
7
-0
.1
16
-0
.1
87
-0
.1
36
0.
00
0
0.
12
0
0.
10
0
0.
06
8
0.
01
3
p
0.
99
9
0.
57
3
0.
64
7
0.
71
9
0.
67
3
0.
53
6
0.
45
9
0.
53
2
0.
52
2
0.
74
0
0.
41
4
0.
18
5
0.
33
6
0.
99
8
0.
41
7
0.
48
1
0.
63
2
0.
92
8
n
58
58
58
58
57
58
58
58
58
58
58
58
58
54
54
58
58
58
M
G
H
r
-0
.0
44
0.
20
7
0.
15
7
-0
.0
72
0.
00
4
0.
09
3
0.
08
0
0.
05
4
0.
03
3
0.
14
6
0.
07
3
-0
.0
11
-0
.1
03
0.
07
3
-0
.0
14
-0
.1
48
0.
20
8
-0
.0
16
p
0.
75
3
0.
13
3
0.
25
8
0.
60
6
0.
98
0
0.
50
3
0.
56
4
0.
69
9
0.
81
3
0.
29
2
0.
60
1
0.
93
9
0.
46
1
0.
61
4
0.
92
1
0.
28
4
0.
13
2
0.
90
6
n
51
51
51
51
50
51
51
51
51
51
51
51
51
47
47
51
51
51
3-
D
G
H
r
-0
.0
37
0.
07
0
0.
04
7
0.
26
4
0.
27
1
0.
27
6
-0
.1
52
0.
30
2
0.
20
7
0.
07
4
-0
.0
12
0.
04
2
0.
07
6
0.
09
9
0.
22
5
0.
13
3
0.
22
7
0.
11
2
p
0.
78
8
0.
61
7
0.
73
8
0.
05
3
0.
04
9
0.
04
4
0.
27
1
0.
02
6
0.
13
3
0.
59
4
0.
93
3
0.
76
1
0.
58
4
0.
49
6
0.
11
7
0.
33
7
0.
09
9
0.
42
0
n
38
38
38
38
38
38
38
38
38
38
38
38
38
35
35
38
38
38
C
M
L
r
-0
.0
88
0.
03
5
0.
00
5
0.
08
7
0.
06
2
-0
.0
69
0.
07
1
-0
.0
84
0.
05
9
0.
12
7
-0
.0
94
-0
.0
01
0.
11
1
-0
.0
96
-0
.0
19
-0
.1
51
0.
17
6
-0
.1
81
p
0.
52
8
0.
80
4
0.
97
4
0.
53
4
0.
66
1
0.
62
0
0.
61
2
0.
54
4
0.
67
1
0.
36
1
0.
49
9
0.
99
7
0.
42
3
0.
50
7
0.
89
7
0.
27
6
0.
20
2
0.
19
1
n
60
60
60
60
59
60
60
60
60
60
60
60
60
56
56
60
60
60
C
E
L
r
-0
.0
13
0.
08
1
0.
06
2
0.
03
6
-0
.1
50
-0
.1
43
-0
.0
09
-0
.0
33
-0
.0
50
0.
07
4
-0
.0
44
0.
04
4
0.
11
7
-0
.1
93
-0
.0
89
-0
.2
18
-0
.0
58
-0
.4
07
p
0.
92
5
0.
56
0
0.
65
4
0.
79
5
0.
28
4
0.
30
2
0.
94
8
0.
81
1
0.
72
0
0.
59
6
0.
75
1
0.
75
2
0.
39
8
0.
18
0
0.
54
1
0.
11
3
0.
67
7
0.
00
2
n
59
59
59
59
58
59
59
59
59
59
59
59
59
55
55
59
59
59
M
et
S
O
r
0.
07
6
0.
01
2
0.
03
0
0.
28
2
-0
.0
15
-0
.0
42
-0
.0
02
0.
05
5
-0
.0
06
-0
.2
39
0.
12
0
0.
06
8
-0
.0
43
0.
06
9
0.
13
2
-0
.1
55
-0
.2
10
-0
.0
89
p
0.
58
7
0.
93
3
0.
83
0
0.
03
9
0.
91
3
0.
76
2
0.
99
0
0.
69
5
0.
96
4
0.
08
2
0.
38
9
0.
62
5
0.
75
8
0.
63
5
0.
35
9
0.
26
4
0.
12
8
0.
52
3
n
60
60
60
60
59
60
60
60
60
60
60
60
60
56
56
60
60
60
F
ru
L
ys
r
-0
.1
25
-0
.1
72
-0
.1
74
0.
03
3
-0
.1
79
-0
.1
12
0.
03
5
-0
.1
47
0.
03
6
-0
.2
68
0.
07
0
0.
15
6
0.
14
5
-0
.1
84
0.
00
8
0.
02
0
-0
.2
79
-0
.0
14
p
0.
36
6
0.
21
4
0.
20
9
0.
81
2
0.
19
9
0.
42
1
0.
80
2
0.
29
0
0.
82
6
0.
05
0
0.
61
3
0.
25
9
0.
29
4
0.
20
0
0.
95
7
0.
88
5
0.
04
1
0.
91
8
n
60
60
60
60
59
60
60
60
60
60
60
60
60
56
56
60
60
60
n,
nu
m
be
r
of
ob
se
rv
at
io
ns
;p
,p
-v
al
ue
ad
ju
st
ed
fo
r
ag
e,
B
M
I,
sm
ok
in
g
st
at
us
,p
as
si
ve
sm
ok
in
g
an
d
ed
uc
at
io
n;
r,
co
rr
el
at
io
n
co
ef
fi
ci
en
t.
A
ss
oc
ia
tio
ns
w
ith
p<
0.
05
ar
e
sh
ow
n
in
bo
ld
pr
in
t.
do
i:1
0.
13
71
/jo
ur
na
l.p
on
e.
01
28
29
3.
t0
05
AGEs and Impaired Fasting Glucose
PLOS ONE | DOI:10.1371/journal.pone.0128293 May 27, 2015 9 / 15
Our finding is in line with results from previous studies in healthy young adults, elderly peo-
ple and even T2D patients [41–43]. One of the aforementioned studies determined circulating
levels of CEL, CML and the cross-linked pentosidine [42]. However, this study found no asso-
ciation between AGEs when analysed separately or combined and markers of glucose metabo-
lism. But there are also conflicting results, suggesting a possible relationship between AGEs,
insulin resistance and insulin secretion. Several research groups examined children and healthy
adults [44–47] as well as diabetes patients without and with comorbidities [48–50] and re-
ported positive relationships between by ELISA-measured AGEs and markers of glucose me-
tabolism. The discrepancy between these results could origin from nutrition, as AGE plasma
levels will increase after dietary intake [16, 51–53] and thus relationships between circulating
AGEs with glucose homeostasis could emerge [50]. Unfortunately, detailed data for dietary
habits were not available in the SALIA cohort.
The trend towards higher MGH1 levels in the IFG group is interesting, because previous
studies found increased MGH1 levels in patients with type 2 diabetes [28] and type 1 diabetes
[54]. These studies indicate that MGH1 levels and impaired glucose metabolism are indeed re-
lated, but it is currently unclear to what extent this link is mediated by fasting or postprandial
hyperglycaemia and which role the duration of impaired glucose metabolism plays in
this context.
We performed a post-hoc power calculation which revealed a power between 5 and 39% to
detect significant differences between the NFG and IFG groups for the tested AGEs. Assuming
that the mean values and standard deviations we measured reflect data in larger populations,
study samples between 200 and 800 individuals would be required to reveal statistical group
differences at α = 0.05 and β = 0.8 e.g. for the free metabolites 3-DF, 3-DPs and 3-DP. This in-
formation should be helpful for the planning of subsequent studies assessing the relationship
between AGEs and hyperglycaemia.
Associations between AGEs and biomarkers of subclinical inflammation
We also evaluated the associations between plasma AGEs and circulating biomarkers for sub-
clinical inflammation. Women with NFG and IFG showed some differences with respect to lev-
els of inflammation-related biomarkers (leptin, TNFα, ratio of HMW/total adiponectin) as
expected. Differences in other diabetes-related cytokines as IL-6 and IL-18 were less pro-
nounced and did not reach statistical significance, which may reflect the moderate sample size
of this pilot study. When assessing associations with AGEs we considered several important
confounders in our extended adjusted models like age, BMI, smoking status (passive or former)
and social status. We observed positive, but rather weak correlations between 3-DGH and
proinflammatory IL-6, IL-18 as well as leptin. This finding is supported by previous studies in
man, reporting no association between CML and pro- and anti-inflammatory mediators as
well as molecules for endothelial cell activation [41, 43, 49, 55]. However, an upregulating effect
of AGEs on inflammatory biomarkers was described for dietary ingested AGEs [45, 55]. Fur-
thermore, findings on AGE effects are conflicting as other studies reported significant positive
associations between CML and CRP as well as IL-6 in diabetic participants [44] and even nega-
tive associations between CML and IL-6 in schoolchildren [47]. However, available data about
associations between AGEs, especially for single compounds from this large group, are scarce
and inhomogeneous.
In addition, MetSO which can be considered as marker of oxidative stress was associated
with increased plasma hsCRP levels [56]. We observed inverse and weak correlations between
TGF-β1 and 3-DF as well as MetSO and FruLys, but not 3-DGH. TGF-β1 may be able reduce
reactive oxygen species [57] and thus oxidative stress, but TGF-β1 also possesses a fibrotic
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potential which was associated with the presence of AGEs in plasma and kidney matrix pro-
teins [58–60]. Furthermore, we observed a rather weak and negative association between lysine
modifications and the cell adhesion molecule sICAM-1. Both structures are thought to be in-
volved in foam cell formation and atherosclerotic lesions [61, 62], but a possible mechanism
linking AGEs and sICAM-1 levels has not yet described.
Strengths and limitations
Our study has several strengths and limitations. First, this study extends the currently available
literature regarding the association between AGEs, their precursors and inflammatory bio-
markers in the circulation. To our knowledge, this is the first study assessing the relationship
between plasma AGEs and subclinical inflammation in nondiabetic study participants. Second,
we measured a variety of immunological mediators in plasma, which are known indicators of
systemic subclinical inflammation reflecting mainly cardiometabolic risk. Third, we used pre-
cise LC-MS/MS measurements instead of antibody-based assays and thus we were able to mea-
sure exact concentrations of each analyte. Furthermore we adjusted our statistical analyses for
potential confounders.
There are also several potential limitations that should be taken into account when inter-
preting our results. We performed a cross-sectional pilot study. Fasting glucose levels have not
been measured in previous SALIA examinations so that we could not analyse associations be-
tween AGE levels and duration of IFG. Furthermore, we examined elderly women. This could
attenuate certain findings due to a survivor effect (individuals with high sensitivity to air pollu-
tion and high levels of inflammation may have died earlier than less susceptible women). Data
on renal function were not available so that the potential relevance of renal clearance on circu-
lating AGE levels could not be assessed. We also had no information on dietary habits of the
study participants. Finally, our study sample was small, so that we may have missed associa-
tions due to limited power (type II error). However, our measurements enabled us to estimate
the sample sizes needed to detect differences between the NFG and IFG groups based on our
observations and may therefore be helpful in the planning of future studies in this field.
Conclusion
After adjusting for potential confounders, circulating plasma protein glycation and oxidation
products as well as glycation intermediates were not increased among elderly women with IFG
compared to women with NFG. AGEs were also not associated with markers of subclinical in-
flammation in this study sample of elderly women. Our post-hoc power calculation indicates
that larger studies are required to reveal associations between AGEs measured using LC-MS/
MS-based methods and early deterioration of glycaemic control before the onset of T2D.
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